The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients

• Status: Completed
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to use Interferon Combined Resveratrol to treat patients with hepatitis B, which may provide a novel therapy target hepatitis B.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Hospital of Jilin University; The First Hospital of Jilin University
• Treatments: Interferons; Resveratrol

Criteria

Inclusion Criteria:

Serologic evidence of chronic hepatitis B infection more than 6 months- HBeAg positive and HBeAb negative； HBV DNA≥20000 IU/ml (equals to 105 copy/ml)； 2×ULN ≤ALT≤10×ULN，TBIL<2×ULN

Exclusion Criteria:

Has history of decompensated liver diseases Has been treated with other anti-virus drugs, or anti-tumor drugs, immuno-suppression drugs Has a history of autoimmune hepatitis History of a severe seizure disorder or current anticonvulsant use History or other evidence of a medical condition associated with chronic liver disease other than HBV which would make the patient, in the opinion of the investigator, unsuitable for the study (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures) History of thyroid disease poorly controlled on prescribed medications, elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease